Esmya
Instructions for use:
- 1. Composition and form of release
- 2. Pharmacological action
- 3. Indications for use
- 4. Contraindications
- 5. Method of administration and dosage regimen
- 6. Use of the drug during pregnancy and breastfeeding
- 7. Side effects
- 8. Drug interactions
- 9. Special instructions for use
- 10. Storage conditions
Esmya is a sex hormone and modulator of the reproductive system function.
Composition and form of release
Esmya is available in tablet form. The active ingredient of each tablet is 5 mg of ulipristal acetate. Additional components: mannitol, microcrystalline cellulose, magnesium stearate, talc, croscarmellose sodium.
In blisters of 14 tablets.
Pharmacological action of Esmiya
According to the instructions, Esmya has an antigestagenic effect.
Ulipristal, when taken orally, becomes an active synthetic selective progesterone receptor modulator, which has a partial tissue-specific antiprogesterone effect.
Indications for the use of Esmiya
According to the instructions, Esmiya or an analogue Esmiya is prescribed as a preoperative therapy for severe and severe symptoms of uterine fibroids for women of reproductive age over eighteen years old. The duration of treatment with a drug or an analogue of Esmiya should not exceed 3 months.
Contraindications
Esmya is contraindicated in the following cases:
- Age under 18;
- Pregnancy and lactation period;
- Hypersensitivity to ulipristal or auxiliary components of the drug;
- Severe form of bronchial asthma, not amenable to correction with oral GCS;
- Bleeding from the vagina of an unexplained nature or for reasons not related to uterine fibroids;
- Cancer of the breast, uterus, ovary, or cervix.
According to reviews, Esimu should not be taken for more than three months, as there is no data on the safety of use for a long period.
With caution, Esmya should be prescribed for bronchial asthma and hepatic or renal failure.
Method of using Esmiya and dosage regimen
According to the instructions, Esmiya should be taken orally, 1 tablet once a day, regardless of food intake. Treatment begins in the first week of the menstrual cycle.
If the patient missed taking the pill, then she should take Esmya as early as possible. If the pill was missed for more than 12 hours, then the drug is skipped, after which the usual pill regimen resumes.
The use of Esmya during pregnancy and breastfeeding
The drug and analogues of Esmiya are strictly contraindicated in pregnancy. In addition, ulipristal is able to pass into breast milk, so there is a risk of harm to the health of children when breastfeeding. Therefore, Esmya is contraindicated during lactation.
Side effects
According to reviews, Esmya can cause the following side effects:
- Nervous system: dizziness, headache.
- Mental disorders: anxiety, emotional disorders.
- Gastrointestinal tract: constipation, dyspepsia, flatulence, abdominal pain, dry mouth, nausea.
- Breasts and genitals: hot flashes, thickening of the endometrium, amenorrhea, ovarian cyst, metrorrhagia, vaginal discharge, discomfort in the mammary glands, breast tenderness.
- Other adverse reactions: vertigo, weight gain, nosebleeds, urinary incontinence, excessive sweating, acne, back pain, muscle and bone pain, asthenia, fatigue, edema.
Drug interactions
Progestogens and hormonal contraceptives can reduce the effectiveness of Esmiya, so they should not be taken simultaneously. Combined use with powerful inhibitors of the isoenzyme CYP3A4 (ritonavir, ketoconazole, nefazodone) leads to an increase in the amount of ulipristal in the blood plasma. And the combined use of Esmiya according to reviews with inducers of the CYP3A4 isoenzyme (carbamazepine, rifampicin, St. John's wort preparations, phenytoin) helps to reduce the concentration of ulipristal in the blood plasma.
Special instructions for the use of Esmiya
According to the instructions, Esmiya should be prescribed to patients only after a thorough examination. Before you start taking Esmya, it is recommended to completely eliminate pregnancy.
Since it is not recommended to use hormonal contraceptives while using Esmiya, it is advisable for women to use non-hormonal methods of contraception during treatment.
Storage conditions
Esmia should be stored in a dark place for no longer than two years.
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
